Mark L. Powell
Novartis (Switzerland), Bristol-Myers Squibb (United States)
Papers
2
Total Citations
47
H-Index
2
About
Mark L. Powell is a pioneering figure in bioanalytical chemistry, whose work has significantly advanced the automation of sample preparation for pharmaceutical analysis. His research focuses on developing robust, high-throughput methods for quantifying drug candidates in biological matrices, with a particular emphasis on antiepileptic agents. Powell’s most notable contribution is the creation of an automated high-performance liquid chromatography (HPLC) method for determining CGP 33101 in human plasma, a potential antiepileptic drug. This method, which integrates laboratory robotics for sample aliquoting, internal standard addition, and buffer mixing, has been cited 24 times, underscoring its impact on streamlining drug development processes. Additionally, Powell introduced an innovative sample preparation technique using pierceable caps to eliminate the need for uncapping sample tubes during transfer, a practical solution that has garnered 23 citations for its efficiency in reducing contamination and handling time. His work has not only enhanced the reliability and speed of bioanalytical assays but also set a standard for automation in pharmaceutical laboratories. Powell’s contributions remain foundational for researchers seeking to optimize drug quantification in clinical and preclinical settings.
Research Focus
Key Achievements
Top Papers
- 1
- 2